Media coverage about Assembly Biosciences (NASDAQ:ASMB) has trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Assembly Biosciences earned a media sentiment score of 0.04 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.5925573660352 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several equities research analysts have recently issued reports on ASMB shares. Zacks Investment Research upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Wednesday, November 15th. Jefferies Group started coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They issued a “buy” rating and a $50.00 target price for the company. BidaskClub lowered shares of Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. ValuEngine lowered shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Finally, B. Riley started coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They issued a “neutral” rating and a $35.00 target price for the company. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $39.25.
Shares of Assembly Biosciences (NASDAQ ASMB) opened at $45.36 on Tuesday. The stock has a market cap of $937.49, a PE ratio of -15.27 and a beta of 0.77. Assembly Biosciences has a twelve month low of $18.60 and a twelve month high of $52.37.
In other news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $46.86, for a total value of $46,860.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 3,000 shares of company stock valued at $141,270 in the last 90 days. Company insiders own 19.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Assembly Biosciences (ASMB) Stock Price” was first published by Stock Observer and is the sole property of of Stock Observer. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thestockobserver.com/2018/02/06/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-assembly-biosciences-asmb-stock-price.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.